Beiersdorf's Share Buyback Fails to Halt Stock's Decade-Low Slide

Beiersdorf shares slump 40% from peak on weak 2026 guidance. Key Q1 report and dividend date approach as analysts downgrade stock.

Despite authorizing a €750 million share repurchase program, Beiersdorf's stock has slumped to its lowest price in ten years. The Hamburg-based consumer goods giant's attempt to signal confidence through capital return has been entirely overlooked by the market, which remains focused on deeper fundamental concerns.

First-Quarter Results and Dividend as Immediate Catalysts

All eyes are now on the company's upcoming first-quarter report, scheduled for release on April 21. This update will be a critical test, revealing whether the market has fully absorbed the company's disappointing guidance or if core brand performance is deteriorating even faster than anticipated. Just four days later, on April 24, the stock will trade ex-dividend. Shareholders are set to receive a payout of €1.00 per share, with distribution following on April 28.

The equity currently trades near a 52-week low of €72.84, a level that places it approximately 25% below its 200-day moving average. Since peaking earlier in the year, the share price has surrendered more than 40% of its value.

Weak Long-Term Guidance Triggers Sell-Off

The primary driver behind the sustained decline is management's underwhelming financial forecast for 2026. Contrary to market expectations for organic sales growth of around 4%, the executive board only projected flat to slightly positive growth. Concurrently, the EBIT margin is expected to dip slightly below the prior year's level of 14.0%. This pressure is attributed to necessary brand investments and rising costs for raw materials and packaging.

Structural challenges in key geographic markets are compounding these issues. Logistics problems are hampering operations in the United States, while the travel retail segment is underperforming in China. This environment has exposed the core Nivea business as being significantly more vulnerable than previously hoped.

Analyst Sentiment Turns Cautious

This pessimistic outlook has drawn a skeptical response from equity researchers. Analysts at Morgan Stanley downgraded the stock to "underweight" and reduced their price target from €84 to €77. Morgan Stanley analyst Tilly Eno pointed to complex challenges facing the Nivea brand, noting that solutions are not immediately visible. Similarly, analysts at Jefferies have expressed doubt regarding management's ability to deliver on its margin promises.

Contrasting Performances and Insider Buying

The full-year 2025 results presented a more mixed picture. The company generated revenue of €9.9 billion, while net profit improved to €955 million. Earnings per share advanced to €4.25. Notably, the dermatology division, anchored by the Eucerin brand, posted robust growth of 11.7%, creating a clear contrast with the struggling mass-market segment.

In a notable move against the prevailing market trend, BBG Holding—the major shareholder via parent company Maxingvest—purchased approximately 242,000 shares between March 6 and March 9. This represents a clear vote of confidence at the current price level, a signal that the broader market has so far chosen to ignore.